Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy (DC-TC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01828762
Recruitment Status : Completed
First Posted : April 11, 2013
Last Update Posted : December 23, 2013
No.85 Hospital, Changning, Shanghai, China
China Cell Technology Ltd. licensed CBMG to conduct the clinical trial as the sponsor in China
Information provided by (Responsible Party):
Cellular Biomedicine Group Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : December 2013
  Study Completion Date : No date given